18F-SynVest-1 PET与18F-FDG PET在认知衰退鉴别诊断中的头对头比较
结果显示18F-SynVesT-1对AD的视觉敏感性和定量AUC均低于18F-FDG,对FTD的分类性能与18F-FDG相似但定量AUC较低。
要点
- 18F-SynVesT-1对AD的视觉敏感性低于18F-FDG(0.57 vs. 0.73),特异性相同(0.76)。
- 18F-SynVesT-1对AD的定量AUC低于18F-FDG(0.71 vs. 0.81;ΔAUC -0.10,95%CI -0.21至0.01)。
- 18F-SynVesT-1对FTD的视觉敏感性和特异性与18F-FDG相似,但定量AUC较低。
核心结论
- 18F-SynVesT-1 PET能够准确分类认知衰退的疾病特异性模式,但对AD的敏感性低于18F-FDG PET。
- 对FTD的分类性能与18F-FDG PET相似,但新皮层结合效应量较低导致AD敏感性降低。
研究设计与样本
- 本研究为头对头比较研究,纳入因认知衰退转诊行18F-FDG PET的患者,随后行18F-SynVesT-1 PET/MRI(距18F-FDG PET 49±26天)。
主要发现
- 在AD和DLB患者中,18F-SynVesT-1 PET显示颞顶叶和楔前叶/后扣带回的减低程度较18F-FDG PET轻(例如AD后扣带回,-10% vs. -20%)。
- 在FTD中,受影响最显著区域的变异较大,通常累及前颞叶和额叶皮层,取决于FTD亚型。
- 视觉评估显示18F-SynVesT-1对AD的敏感性低于18F-FDG(0.57 vs. 0.73),特异性相同(0.76)。
- 定量分析显示18F-SynVesT-1对AD的AUC低于18F-FDG(0.71 vs. 0.81;ΔAUC -0.10;95%CI -0.21至0.01)。
- 对FTD,18F-SynVesT-1视觉分类的敏感性和特异性(0.58和0.90)与18F-FDG(0.50和0.93)相似,但定量AUC较低(0.64 vs. 0.76;ΔAUC -0.12;95%CI -0.27至0.04)。
关键数值与推荐
- 非劣效性定义为AUC差值(ΔAUC)的95%CI下限不低于-0.10,以临床随访诊断为金标准。
- AD的ΔAUC为-0.10(95%CI -0.21至0.01),FTD的ΔAUC为-0.12(95%CI -0.27至0.04)。
临床怎么用
- 18F-SynVesT-1 PET可用于认知衰退的疾病特异性模式分类,但对AD的鉴别敏感性低于18F-FDG PET,临床选择显像剂时需考虑此差异。
局限性
- 需要更大样本研究以正式评估该示踪剂在所有亚组中的非劣效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although 18F-FDG PET is commonly used in the differential diagnosis of cognitive decline, synaptic vesicle glycoprotein 2A PET may offer a more direct assessment of synaptic integrity and address limitations associated with 18F-FDG, such as sensitivity to sensory stimuli and glycemic variations. In this study, a head-to-head comparison of 18F-SynVesT-1 and 18F-FDG was performed for differentiating causes of cognitive decline in a tertiary clinical setting. Methods: Patients with cognitive decline referred for 18F-FDG PET were recruited to undergo 18F-SynVesT-1 PET/MRI (49 ± 26 d after 18F-FDG PET). Diagnosis was determined by routine clinical follow-up (median, 11 mo) and classified as Alzheimer disease (AD), frontotemporal degeneration (FTD), dementia with Lewy bodies (DLB), other neurodegenerative disorders (ONDs), or nonneurodegenerative disorders (NoNDs). Volume-wise and voxelwise semiquantitative analyses were performed using tracer-specific healthy volunteers. Diagnostic accuracy for both tracers was evaluated through logistic regression and by consensus from 3 readers. Noninferiority was defined by an area-under-the-curve margin (ΔAUC) of -0.10 within a 95% CI, using the clinical follow-up diagnosis as the gold standard. Results: Ninety-four patients were included: 44 with AD, 12 with FTD, 4 with DLB, 5 with ONDs, and 29 with NoNDs. Volume-wise and voxelwise analyses showed that, in patients with AD and DLB, reductions in the temporoparietal and precuneus/posterior cingulate were less pronounced with 18F-SynVesT-1 PET than with 18F-FDG PET (e.g., posterior cingulate in AD, -10% vs. -20%). In FTD, the most impacted areas showed greater variability, typically affecting the anterior temporal and frontal cortices, depending on the FTD subtype. Visual assessment showed lower sensitivity for AD with 18F-SynVesT-1 PET than with 18F-FDG PET (0.57 vs. 0.73) with equal specificity (0.76), whereas quantitative analysis yielded a lower area under the curve (0.71 vs. 0.81; ΔAUC, -0.10; 95% CI, -0.21 to 0.01). For FTD, 18F-SynVesT-1 visual classification yielded similar sensitivity and specificity (0.58 and 0.90) compared with 18F-FDG (0.50 and 0.93) but a lower quantitative area under the curve (0.64 vs. 0.76; ΔAUC, -0.12; 95% CI, -0.27 to 0.04). Conclusion: 18F-SynVesT-1 PET enabled accurate classification of disease-specific patterns of cognitive decline. Although classification performance for FTD was similar to that of 18F-FDG PET, the lower effect size in neocortical binding resulted in lower sensitivity for AD. Larger study samples are needed to formally evaluate tracer noninferiority in this clinical context for all subgroups.
引用
- Carron C, Boeckxstaens L, Degryse L, et al. Head-to-Head Comparison of 18F-SynVest-1 PET and 18F-FDG PET in the Differentiation of Patients with Cognitive Decline. J Nucl Med. 2026. PMID: 42914183. doi:10.2967/jnumed.126.272646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。